Background: Pancreatic ductal adenocarcinoma (PDAC) remains a formidable challenge in oncology, characterized by a high mortality rate, largely attributable to delayed diagnosis and the intricacies of its tumor microenvironment. Innovations in modeling pancreatic epithelial transformation provide valuable insights into the pathogenesis and potential therapeutic strategies for PDAC. Methods: We employed a porcine model, utilizing the Ad-K8-Cre adenoviral vector, to investigate the effects of variable doses (107 to 1010 pfu) on pancreatic epithelial cells. This vector, driven by a Keratin-8 promoter, delivers Cre-recombinase specifically to pancreatic epithelial cells. Intraductal pancreatic injections in transgenic Oncopigs (LSL-KRASG12D-TP53R167H) were performed to evaluate epithelial cell proliferation and stromal response in a dose-dependent manner. Results: Specificity of the adenoviral vector was validated through Keratin-8 expression and Cre-recombinase activity. We observed that the extent of macroscopic and histological alterations was dose-dependent. Higher doses resulted in significant tissue morphology changes, including atrophy and enlarged lymph nodes. Microscopic examination revealed concentration-dependent neoplastic transformation, characterized by ductal proliferation, cellular atypia, and stromal alterations. Notably, activation of the KRASG12D mutation corresponded with increased epithelial proliferation. Desmoplastic responses were evident through vimentin, α-SMA, and Masson's trichrome staining, indicating progressive collagen deposition, particularly at elevated viral titers. Conclusion: Our study suggests a distinct dose-response relationship of Ad-K8-Cre in inducing pancreatic epithelial proliferation and neoplasia in an Oncopig model. While lower doses induced controlled epithelial proliferation, higher doses precipitated pronounced neoplastic and stromal alterations. These findings suggest the ability for precision in gene activation and high-light the potential to modulate the pancreatic tumor microenvironment in large animal preclinical models. The Oncopig model may emerge as an important tool in PDAC research, with clinically relevant pathology in a human-sized experimental model.